Diversify Wealth Management LLC Raises Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Diversify Wealth Management LLC raised its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 63.8% during the fourth quarter, Holdings Channel.com reports. The firm owned 15,464 shares of the biopharmaceutical company’s stock after buying an additional 6,025 shares during the period. Diversify Wealth Management LLC’s holdings in Halozyme Therapeutics were worth $816,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in HALO. Envestnet Asset Management Inc. grew its position in Halozyme Therapeutics by 4.9% in the second quarter. Envestnet Asset Management Inc. now owns 229,620 shares of the biopharmaceutical company’s stock valued at $12,023,000 after acquiring an additional 10,651 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Halozyme Therapeutics by 12.4% during the second quarter. Dimensional Fund Advisors LP now owns 1,897,759 shares of the biopharmaceutical company’s stock valued at $99,363,000 after purchasing an additional 209,530 shares during the period. Mercer Global Advisors Inc. ADV acquired a new position in Halozyme Therapeutics during the second quarter worth about $182,000. Vanguard Personalized Indexing Management LLC boosted its position in shares of Halozyme Therapeutics by 13.5% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 20,711 shares of the biopharmaceutical company’s stock valued at $1,084,000 after purchasing an additional 2,463 shares during the period. Finally, Intech Investment Management LLC acquired a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at $1,192,000. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Halozyme Therapeutics Stock Up 2.1 %

Halozyme Therapeutics stock opened at $55.94 on Wednesday. Halozyme Therapeutics, Inc. has a fifty-two week low of $33.15 and a fifty-two week high of $65.53. The stock has a market cap of $7.12 billion, a PE ratio of 18.52, a price-to-earnings-growth ratio of 0.42 and a beta of 1.24. The firm’s 50-day simple moving average is $49.50 and its 200 day simple moving average is $54.14. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. JMP Securities lifted their price target on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a report on Friday, November 1st. Wells Fargo & Company lowered their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. HC Wainwright lifted their target price on Halozyme Therapeutics from $68.00 to $70.00 and gave the company a “buy” rating in a research note on Friday, January 10th. Piper Sandler increased their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research note on Friday, January 10th. Finally, Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $60.89.

Insider Activity

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 10,000 shares of the stock in a transaction on Monday, January 6th. The shares were sold at an average price of $50.01, for a total transaction of $500,100.00. Following the completion of the sale, the director now owns 43,611 shares of the company’s stock, valued at $2,180,986.11. This represents a 18.65 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 2.70% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.